Dual Targeted Immunotherapy via In Vivo Delivery of Biohybrid RNAi‐Peptide Nanoparticles to Tumor‐Associated Macrophages and Cancer Cells
- 1 June 2015
- journal article
- research article
- Published by Wiley in Advanced Functional Materials
- Vol. 25 (27), 4183-4194
- https://doi.org/10.1002/adfm.201501283
Abstract
Lung cancer is associated with very poor prognosis and considered one of the leading causes of death worldwide. Here, highly potent and selective biohybrid RNA interference (RNAi)‐peptide nanoparticles (NPs) are presented that can induce specific and long‐lasting gene therapy in inflammatory tumor associated macrophages (TAMs), via an immune modulation of the tumor milieu combined with tumor suppressor effects. The data here prove that passive gene silencing can be achieved in cancer cells using regular RNAi NPs. When combined with M2 peptide–based targeted immunotherapy that immuno‐modulates TAMs cell population, a synergistic effect and long‐lived tumor eradication can be observed along with increased mice survival. Treatment with low doses of siRNA (ED50 0.0025–0.01 mg kg−1) in a multi and long‐term dosing system substantially reduces the recruitment of inflammatory TAMs in lung tumor tissue, reduces tumor size (≈95%), and increases animal survival (≈75%) in mice. The results here suggest that it is likely that the combination of silencing important genes in tumor cells and in their supporting immune cells in the tumor microenvironment, such as TAMs, will greatly improve cancer clinical outcomes.This publication has 45 references indexed in Scilit:
- Targeted delivery of proapoptotic peptides to tumor-associated macrophages improves survivalProceedings of the National Academy of Sciences of the United States of America, 2013
- Topical delivery of siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulationProceedings of the National Academy of Sciences of the United States of America, 2012
- Bronchoalveolar lavage cell pattern from healthy human lungClinical and Experimental Immunology, 2011
- Therapeutic siRNA silencing in inflammatory monocytes in miceNature Biotechnology, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cellsProceedings of the National Academy of Sciences of the United States of America, 2010
- Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticlesNature, 2010
- Small silencing RNAs: State-of-the-artAdvanced Drug Delivery Reviews, 2009
- Sequence- and target-independent angiogenesis suppression by siRNA via TLR3Nature, 2008
- Tumour-educated macrophages promote tumour progression and metastasisNature Reviews Cancer, 2004